{"groups":[{"description":"260 mg once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle","id":"FG000","title":"Milademetan (RAIN-32)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"10"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"40"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"26"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All enrolled participants (40 participants) received the study medication. Twenty-eight (28) discontinued treatment. Fourteen (14) completed the study."}